Cognito Therapeutics, a Cambridge neurotech startup, has locked in a $105 million financing round to drive its at-home Alzheimer’s therapy toward an FDA submission. The cash infusion lands just as the company approaches a pivotal trial readout and gears up for the regulatory and manufacturing work that would be needed if the data support a filing.
The Series C round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with New Vintage, Apollo Health Ventures and Benvolio Group also joining in. The raise brings Cognito’s total private funding to about $233 million, according to STAT, as backers place a sizable bet on a non-drug approach that the company says can be used at home and scaled beyond traditional clinic visits.
Cognito’s lead product, Spectris, combines gamma-frequency visual stimulation with synchronized sound, delivered through a glasses-style visor and over-ear headphones for roughly an hour a day. The company says the stimulation is designed to evoke gamma brain rhythms associated with memory and to slow structural decline, according to BusinessWire. Earlier feasibility work and Phase 2 reporting cited in company materials linked the device to smaller declines in cognition and less MRI-measured brain atrophy in treated participants compared with controls.
Trial status and path to the FDA
The company says its pivotal HOPE study is fully enrolled and that it is now analyzing data that will shape a potential regulatory filing, according to Cognito Therapeutics. The fresh $105 million arrives as Cognito prepares to bundle those results for regulators, a timeline first detailed by the Boston Business Journal.
What the funding buys
Cognito did not immediately break down how it plans to allocate the new round when asked, but in past funding announcements the company said similar capital would help speed late-stage development, manufacturing readiness and commercialization plans, according to BusinessWire. Spectris already holds an FDA Breakthrough Device designation, which can give companies a faster track to agency feedback on clinical and regulatory strategy.
For now, investors and patients are waiting on the HOPE topline results and any formal filing timeline the company sets. Cognito says participants across its studies have completed more than 100,000 treatment sessions so far, a figure that underscores the home-use scale the company is aiming for, according to Cognito Therapeutics. If the pivotal data are strong, Spectris could join a small but growing set of non-drug interventions that aim to change the course of Alzheimer’s care, a development that will depend on clear, reproducible results and regulator confidence before any broad rollout.
